Аналіз змін системи згортання крові у хворих на гіпертонічну хворобу в поєднанні з хронічним обструктивним захворюванням легень різного ступеня важкості

Aim of research was to determine the influence of COPD severity on the plasma hemostasis condition in patients with HT combined with COPD.Materials and methods. 79 patients were examined: 15 almost healthy (control) and 64 patients with stage II HT with concomitant COPD. Depending on the COPD severity, the patients were divided into 3 groups: group A- 11 patients with HT and COPD of the I severity degree; Group B - 28 patients with HT and COPD of the II severity degree; Group B - 25 patients HT and COPD of the III severity degree. Special laboratory tests: coagulation indicators - activated partial thromboplastin time, prothrombin time, thrombin time, fibrinogen, soluble fibrin monomer complexes, ancistron test, Lebetox test, and echitox test were carried out.Results: in result of the study it was found that comorbid HT and COPD course is characterized by increased activity of hemostasis system coagulation level, which intensity is associated with bronchial obstruction severity. In particular, COPD of the III severity degree hyperfibrinogenemia, as well as soluble fibrin monomer complexes significant increase were observed in all subgroups of the patients with HT and COPD, accompanied by activation of external pathway of coagulation and combined with accelerated processes of prothrombinase-,  trombino- and fibrin formation according to specific snake venoms tests.Conclusion. Comorbid HT and COPD course is characterized by the activation of hemostasis system coagulation level, which intensity is associated with bronchial obstruction severity. Hyperfibrinogenemia and a significant increase of the SFMC content, observed in all subgroups of the patients with HT and COPD, at COPD of the III severity degree are accompanied by activation of external pathway of coagulation and combined with accelerated processes of prothrombinase-,  trombino- and fibrin formation according to specific snake venoms tests. The patients with HT combined with COPD of the III severity degree need careful laboratory monitoring to solve the problem of the additional antithrombotic correction necessityМетою дослідження було встановити вплив ступеню важкості хронічного обструктивного захворювання легень  на стан плазмового гемостазу у хворих із поєднаним перебігом гіпертонічної хвороби та ХОЗЛ. В результаті роботи виявлено, що коморбідний перебіг ГХ та ХОЗЛ характеризується підвищенням активності згортуючої ланки системи гемостазу, вираженість якої асоціюється із ступенем важкості бронхообструкці

Old Slavonic language as a didactic resource for developing a strong language student personality

The article considers the axiological potential of the Old Slavic language in connection with the problem of formation of the linguistic personality of the philologist. Special attention is paid to the axiological guidelines of modern pedagogical education: the development of a value attitude towards language as part of national history, culture, spirituality. Some aspects of the formation of a strong language personality are presented on the example of the language personality of the future verbal teacher. The aim of the study is to describe didactic possibilities of the language-preservative in the process of training the teacher-verbal are described: formation of attitude to the native language and historical path of its development as wealth and value, which contribute to unification and consolidation of the people speaking this language. The Old Slavonic (Church Slavonic) language appears to be a preservative language for the Russian language at all periods of its existence and, in this regard, becomes a methodological basis, an integrative base for the study of the history of the Russian language. This provision concerns the historical grammar of the Russian language, the history of the Russian literary language as the main educational disciplines of historical and linguistic training of a specialist-philologist. The methodological basis is a conception of linguistic rhetorical education of strong linguistic personality. For ancient languages we propose to implement the conception by linguistic methods of lexico-stylistic analysis, axiological approach to language study, method of modeling of integrative text didactic material. The results of the study show the mastering of the vocabulary of the Old Slavic language contributes to the expansion and deepening of linguistic competences and linguistic ethics of the philologist. As a result of successful practice of using case texts there is presented a version of integrative didactic material based on hagiography literature of Ancient Russia

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma

Background: the proteasome inhibitor bortezomib was initially approved for the treatment of relapsed mantle-cell lymphoma. We investigated whether substituting bortezomib for vincristine in frontline therapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) could improve outcomes in patients with newly diagnosed mantle-cell lymphoma. Methods: in this phase 3 trial, we randomly assigned 487 adults with newly diagnosed mantle-cell lymphoma who were ineligible or not considered for stem-cell transplantation to receive six to eight 21-day cycles of R-CHOP intravenously on day 1 (with prednisone administered orally on days 1 to 5) or VR-CAP (R-CHOP regimen, but replacing vincristine with bortezomib at a dose of 1.3 mg per square meter of body-surface area on days 1, 4, 8, and 11). The primary end point was progression-free survival. Results: after a median follow-up of 40 months, median progression-free survival (according to independent radiologic review) was 14.4 months in the R-CHOP group versus 24.7 months in the VR-CAP group (hazard ratio favoring the VR-CAP group, 0.63; P<0.001), a relative improvement of 59%. On the basis of investigator assessment, the median durations of progression-free survival were 16.1 months and 30.7 months, respectively (hazard ratio, 0.51; P<0.001), a relative improvement of 96%. Secondary end points were consistently improved in the VR-CAP group, including the complete response rate (42% vs. 53%), the median duration of complete response (18.0 months vs. 42.1 months), the median treatment-free interval (20.5 months vs. 40.6 months), and the 4-year overall survival rate (54% vs. 64%). Rates of neutropenia and thrombocytopenia were higher in the VR-CAP group. Conclusions: VR-CAP was more effective than R-CHOP in patients with newly diagnosed mantle-cell lymphoma but at the cost of increased hematologic toxicity. (Funded by Janssen Research and Development and Millennium Pharmaceuticals; LYM-3002 ClinicalTrials.gov number, NCT00722137)

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

[EN]The purpose of this study was to confirm overall survival (OS) and other clinical benefits with bortezomib, melphalan, and prednisone (VMP) versus melphalan and prednisone (MP) in the phase III VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma) trial after prolonged follow-up, and evaluate the impact of subsequent therapies. Previously untreated symptomatic patients with myeloma ineligible for high-dose therapy received up to nine 6-week cycles of VMP (n = 344) or MP (n = 338). With a median follow-up of 36.7 months, there was a 35% reduced risk of death with VMP versus MP (hazard ratio, 0.653; P < .001); median OS was not reached with VMP versus 43 months with MP; 3-year OS rates were 68.5% versus 54.0%. Response rates to subsequent thalidomide- (41% v 53%) and lenalidomide-based therapies (59% v 52%) appeared similar after VMP or MP; response rates to subsequent bortezomib-based therapy were 47% versus 59%. Among patients treated with VMP (n = 178) and MP (n = 233), median survival from start of subsequent therapy was 30.2 and 21.9 months, respectively, and there was no difference in survival from salvage among patients who received subsequent bortezomib, thalidomide, or lenalidomide. Rates of adverse events were higher with VMP versus MP during cycles 1 to 4, but similar during cycles 5 to 9. With VMP, 79% of peripheral neuropathy events improved within a median of 1.9 months; 60% completely resolved within a median of 5.7 months. VMP significantly prolongs OS versus MP after lengthy follow-up and extensive subsequent antimyeloma therapy. First-line bortezomib use does not induce more resistant relapse. VMP used upfront appears more beneficial than first treating with conventional agents and saving bortezomib- and other novel agent-based treatment until relapse

ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution

Over the past decade, we have seen a significant change in modern approaches in the first-line treatment of chronic lymphocytic leukemia (CLL). The CLL-10 study data established the FCR regimen as the treatment of choice for younger patients with limited comorbidities, while for patients older than 65 years, the BR regimen is more often considered as less toxic one. According to published data, 46% of patients with newly diagnosed CLL have comorbidities. Moreover, high-risk patients with del(17p) and/or TP53 mutation do not have response on immunochemotherapy (ICT) most often. Thus, about 1/2 of the patients cannot be treated or will not respond to standard ICT regimens. Targeted therapy with Brutons tyrosine kinase (BTK) inhibitors is an important option of the first-line treatment of patients with CLL. Acalabrutinib is a highly selective second-generation BTK inhibitor that does not inhibit EGFR, ITK or TEC targets. Acalabrutinib in combination with obinutuzumab or as monotherapy can be considered as a highly effective and safe option of the first line of CLL therapy. Based on the hight selectivity of the agent, acalabrutinib can be considered as the preferable option for patients who are not eligible for ICT, including patients with commodities, such as cardiovascular diseases or risk factors for their development

Thermodynamic Reassessment of the Na-Cu and Na-K Binary Systems

International audienceThe Na-Cu and Na-K systems are of significant interest due to the use of liquid sodium and melt of sodium and potassium in the nuclear industry as a cooling agent in nuclear reactors. In the present work, thermodynamic modeling of phase equilibria in the Na-Cu and Na-K systems is carried out, based on the available published experimental data. This modeling was done using the “FactSage” software package (version 7.0). The set of Redlich-Kister equation parameters was obtained, which allows one to describe the dependence of Gibbs energy from composition and temperature for solutions that can be formed in the studied systems. Phase diagrams (T-x diagrams) of the investigated systems were calculated

Peculiarities of platelet hemostasis changes in COPD - hypertensive disease mixed patients

Samoilova Svitlana O., Plenova Olga M. Peculiarities of platelet hemostasis changes in COPD - hypertensive disease mixed patients. Journal of Education, Health and Sport. 2016;6(4):39-44. eISSN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.49394 http://ojs.ukw.edu.pl/index.php/johs/article/view/3445   The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 755 (23.12.2015). 755 Journal of Education, Health and Sport eISSN 2391-8306 7 © The Author (s) 2016; This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 05.03.2016. Revised 20.03.2016. Accepted: 05.04.2016.     Peculiarities of platelet hemostasis changes in COPD - hypertensive disease mixed patients   Svitlana O. Samoilova, Olga M. Plenova   O.O.Bohomolets National Medical University   Abstract   Disorders in the hemostasis system have a major impact on the disease course and complication in the hypertensive disease and chronic obstructive pulmonary disease patients. To assess the platelet hemostasis we examined 62 persons: 15 apparently healthy (Control Group), 15 HD patients without COPD, 17 HD patients with COPD associated, and 15 COPD patients of Degree II and III. We have found out that HD, COPD and the mix patients demonstrate an increased thrombocyte functional activity expressed in a higher degree of spontaneous aggregation, and significant activation of arachidonic acid induced thrombocyte aggregation. The HD patients feature a specific increase of adrenalin induced aggregation, contrary to other examined groups, that may be explained by a role of sympathetic nervous system in the HD pathogenesis. Chronic inflammation in the COPD patients is accompanied with a significant increase of arachidonic acid thrombocyte reaction (the highest among all examined groups) that should be taken into account when establishing a treatment policy with anti-inflammatory agents included.   Key words: hypertensive disease, chronic obstructive pulmonary diseases, hemostasis, thrombocytes, aggregation

High-Temperature Oxidation of High-Entropic Alloys: A Review

Over the past few years, interest in high-entropic alloys (HEAs) has been growing. A large body of research has been undertaken to study aspects such as the microstructure features of HEAs of various compositions, the effect of the content of certain elements on the mechanical properties of HEAs, and, of course, special properties such as heat resistance, corrosion resistance, resistance to irradiation with high-energy particles, magnetic properties, etc. However, few works have presented results accumulated over several years, which can complicate the choice of directions for further research. This review article presents the results of studies of the mechanisms of high-temperature oxidation of HEAs of systems: Al-Co-Cr-Fe-Ni, Mn-Co-Cr-Fe-Ni, refractory HEAs. An analysis made it possible to systematize the features of high-temperature oxidation of HEAs and propose new directions for the development of heat-resistant HEAs. The presented information may be useful for assessing the possibility of the practical application of HEAs in the aerospace industry, in nuclear and chemical engineering, and in new areas of energy